

Jeantine E Lunshof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5091385/publications.pdf>

Version: 2024-02-01

58
papers

2,264
citations

279487

23
h-index

223531

46
g-index

63
all docs

63
docs citations

63
times ranked

3079
citing authors

#	ARTICLE	IF	CITATIONS
1	From genetic privacy to open consent. <i>Nature Reviews Genetics</i> , 2008, 9, 406-411.	7.7	385
2	A public resource facilitating clinical use of genomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11920-11927.	3.3	194
3	The Genome Project-Write. <i>Science</i> , 2016, 353, 126-127.	6.0	194
4	The ethics of experimenting with human brain tissue. <i>Nature</i> , 2018, 556, 429-432.	13.7	139
5	Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. <i>Pharmacogenomics Journal</i> , 2005, 5, 221-225.	0.9	119
6	Misdirected precaution. <i>Nature</i> , 2008, 456, 34-35.	13.7	95
7	Harvard Personal Genome Project: lessons from participatory public research. <i>Genome Medicine</i> , 2014, 6, 10.	3.6	90
8	Children and Population Biobanks. <i>Science</i> , 2009, 325, 818-819.	6.0	84
9	Addressing the ethical issues raised by synthetic human entities with embryo-like features. <i>ELife</i> , 2017, 6, .	2.8	77
10	Core commitments for field trials of gene drive organisms. <i>Science</i> , 2020, 370, 1417-1419.	6.0	67
11	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. <i>Pharmacogenomics</i> , 2019, 20, 643-657.	0.6	65
12	Personal genomes in progress: from the Human Genome Project to the Personal Genome Project. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 47-60.	1.8	64
13	Ethical issues related to brain organoid research. <i>Brain Research</i> , 2020, 1732, 146653.	1.1	63
14	Raw Personal Data: Providing Access. <i>Science</i> , 2014, 343, 373-374.	6.0	57
15	Guidance on stakeholder engagement practices to inform the development of area-wide vector control methods. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007286.	1.3	48
16	A call for the creation of personalized medicine databases. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 23-26.	21.5	47
17	Revisiting the Warnock rule. <i>Nature Biotechnology</i> , 2017, 35, 1029-1042.	9.4	47
18	Mice Against Ticks: an experimental community-guided effort to prevent tick-borne disease by altering the shared environment. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20180105.	1.8	42

#	ARTICLE	IF	CITATIONS
19	Emergence of the silicon human and network targeting drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 190-197.	1.9	32
20	Personalized medicine: decades away?. <i>Pharmacogenomics</i> , 2006, 7, 237-241.	0.6	31
21	Health technology assessment in the era of personalized health care. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 118-126.	0.2	28
22	Regulate gene editing in wild animals. <i>Nature</i> , 2015, 521, 127-127.	13.7	25
23	Adaptive Risk Management of Gene Drive Experiments. <i>Applied Biosafety</i> , 2017, 22, 97-103.	0.2	24
24	Pharmacogenomic Testing: Knowing More, Doing Better. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 387-389.	2.3	18
25	Hippocrates revisited? Old ideals and new realities. <i>Genomic Medicine</i> , 2008, 2, 1-3.	0.6	17
26	Applications and ethics of computer-designed organisms. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 655-656.	16.1	16
27	Reactions to the National Academies/Royal Society Report on <i>Heritable Human Genome Editing</i> . <i>CRISPR Journal</i> , 2020, 3, 332-349.	1.4	15
28	Social license and synthetic biology: the trouble with mining terms. <i>Journal of Responsible Innovation</i> , 2020, 7, 280-297.	2.3	15
29	Human germ line editing's roles and responsibilities. <i>Protein and Cell</i> , 2016, 7, 7-10.	4.8	13
30	Personalized medicine: how much can we afford? A bioethics perspective. <i>Personalized Medicine</i> , 2005, 2, 43-47.	0.8	12
31	Anomalous COVID-19 tests hinder researchers. <i>Science</i> , 2021, 371, 244-245.	6.0	11
32	Personalized medicine: new perspectives – new ethics?. <i>Personalized Medicine</i> , 2006, 3, 187-194.	0.8	10
33	Laboratory-Generated DNA Can Cause Anomalous Pathogen Diagnostic Test Results. <i>Microbiology Spectrum</i> , 2021, 9, e0031321.	1.2	10
34	Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. <i>Pharmacogenomics</i> , 2007, 8, 519-519.	0.6	9
35	Governing Gene Drive Technologies: A Qualitative Interview Study. <i>AJOB Empirical Bioethics</i> , 2022, 13, 107-124.	0.8	9
36	Teaching and practicing pharmacogenomics: a complex matter. <i>Pharmacogenomics</i> , 2006, 7, 243-246.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Personalized Pharmacotherapy: Genotypes, Biomarkers, and Beyond. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 142-142.	2.3	8
38	A focus on personal genomics. <i>Personalized Medicine</i> , 2009, 6, 603-606.	0.8	8
39	An unbiased index to quantify participant's phenotypic contribution to an open-access cohort. <i>Scientific Reports</i> , 2017, 7, 46148.	1.6	6
40	Brain Surrogates "Empty or Full Makes the Difference. <i>American Journal of Bioethics</i> , 2021, 21, 46-48.	0.5	6
41	Personalized participatory medicine: sharing knowledge and uncertainty. <i>Genome Medicine</i> , 2011, 3, 69.	3.6	5
42	Editorial: Genetic and Genomic Research "Changing Patterns of Accountability. <i>Accountability in Research</i> , 2011, 18, 121-131.	1.6	5
43	Our genomes today: time to be clear. <i>Genome Medicine</i> , 2013, 5, 52.	3.6	5
44	Pharmacogenomics, drug development, and ethics: Some points to consider. <i>Drug Development Research</i> , 2004, 62, 112-116.	1.4	4
45	Ancestry in translational genomic medicine: handle with care. <i>Genome Medicine</i> , 2009, 1, 24.	3.6	4
46	Whole genomes, small children, big questions. <i>Personalized Medicine</i> , 2012, 9, 667-669.	0.8	4
47	Response "Biobanks. <i>Science</i> , 2009, 326, 799-799.	6.0	2
48	Guarding children's genetic privacy. <i>Nature</i> , 2013, 494, 430-430.	13.7	2
49	Raw Data: Access to Inaccuracy "Response. <i>Science</i> , 2014, 343, 969-969.	6.0	2
50	Response to Sykiotis and Papavassiliou: Professional education in molecular medicine " pharmacogenetics first. <i>Trends in Molecular Medicine</i> , 2005, 11, 485-486.	3.5	1
51	A deserving role for the National Center for Advancing Translational Sciences. <i>Lancet, The</i> , 2011, 377, 1745-1746.	6.3	1
52	Minibrains: What's in a Name?. <i>American Scientist</i> , 2021, 109, 208.	0.1	1
53	Voices of biotech leaders. <i>Nature Biotechnology</i> , 2021, 39, 654-660.	9.4	1
54	Short literature notices. <i>Medicine, Health Care and Philosophy</i> , 2005, 8, 261-264.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Interview. <i>Personalized Medicine</i> , 2008, 5, 215-218.	0.8	0
56	<i>Genomics, inconvenient truths and accountability.</i> , 0, , 116-130.		0
57	Reciprocity and transparency: Normative principles of data sharing. <i>Applied & Translational Genomics</i> , 2014, 3, 122-123.	2.1	0
58	Implications of Mitochondrial Dysfunction for the Anesthetic and Perioperative Management. <i>A&A Practice</i> , 2018, 10, 103-106.	0.2	0